Results 1 to 10 of about 164 (107)

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis

Neurology and Therapy, 2022
Introduction Adherence to disease-modifying therapies is key for achieving optimal outcomes in multiple sclerosis (MS). Diroximel fumarate (DRF) is an oral fumarate approved for treatment of relapsing forms of MS. It has the same pharmacologically active
Brittney Lager, Ivan Božin, Sai L Shankar   +2 more
exaly   +6 more sources

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

Therapeutic Advances in Neurological Disorders, 2021
Background: Diroximel fumarate (DRF) is a novel oral fumarate approved for relapsing forms of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) tolerability versus dimethyl fumarate (DMF) with fewer days of Individual
Annette Wundes, Elżbieta Jasińska, Tjalf Ziemssen   +2 more
exaly   +5 more sources

Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data

Drug Design, Development and Therapy, 2022
Larissa Hauer,1 Johann Sellner2 1Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria; 2Department of Neurology, Landesklinikum Mistelbach-Gänserndorf ...
Larissa Hauer, Johann Sellner
exaly   +5 more sources

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

Journal of Comparative Effectiveness Research
Aim: Diroximel fumarate (DRF), ozanimod (OZA) and interferon beta-1a (IFN) are disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No randomized trials have compared DRF versus OZA and IFN. We compared DRF versus OZA
Tammy Jiang, Ivan Božin, Mark S Freedman   +2 more
exaly   +3 more sources

Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility? [PDF]

Pharmaceuticals, 2020
Fumaric acid esters (FAEs) are small molecules with anti-oxidative, anti-inflammatory and immune-modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing ...
Stephanie Kourakis, Cara A. Timpani, Judy B. de Haan, Nuri Gueven, Dirk Fischer, Emma Rybalka   +5 more
doaj   +4 more sources

Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis

Journal of Comparative Effectiveness Research
Aim: This study compares the efficacy of diroximel fumarate (DRF) with ocrelizumab (OCR) and interferon beta-1a (IFNβ-1a) for treating relapsing multiple sclerosis (MS) through matching-adjusted indirect comparisons (MAICs).
Carrie M Hersh, Yolanda Aladro-Benito, James B Lewin   +2 more
exaly   +5 more sources

Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl Fumarate) on NRF2, NF-kappaB and IRF1 Pathway Genes

Pharmaceuticals, 2022
Dimethyl fumarate (DMF) has emerged as a first-line therapy for relapsing-remitting multiple sclerosis (RRMS). This treatment, however, has been limited by adverse effects, which has prompted development of novel derivatives with improved tolerability ...
William R. Swindell, Krzysztof Bojanowski, Ratan K. Chaudhuri   +2 more
doaj   +2 more sources

Comparative activity of dimethyl fumarate derivative IDMF in three models relevant to multiple sclerosis and psoriasis

FEBS Open Bio
Dimethyl fumarate (DMF) is an anti‐inflammatory and immunoregulatory medication used to treat multiple sclerosis (MS) and psoriasis. Its skin sensitization property precludes its topical use, which is unfortunate for the treatment of psoriasis ...
Yulin He, Guiyi Gong, Geovani Quijas, Simon Ming‐Yuen Lee, Ratan K. Chaudhuri, Krzysztof Bojanowski   +5 more
doaj   +2 more sources

Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”

Neurology and Therapy, 2023
Pelayo Nieto-Gómez, Celia Castaño-Amores   +1 more
exaly   +2 more sources

Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”

Neurology and Therapy, 2023
Brittney Lager, Ivan Božin, Sai L Shankar   +2 more
exaly   +2 more sources